BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets).
John M. Kirkwood
No relevant relationships to disclose
Georgina V. Long
Consultant or Advisory Role - GlaxoSmithKline
Other Remuneration - GlaxoSmithKline
Uwe Trefzer
Consultant or Advisory Role - GlaxoSmithKline
Michael A. Davies
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Paolo Antonio Ascierto
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Roche/Genentech
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Roche/Genentech
Paul B. Chapman
Consultant or Advisory Role - GlaxoSmithKline; Roche/Genentech
Research Funding - GlaxoSmithKline; Roche/Genentech
Igor Puzanov
Consultant or Advisory Role - GlaxoSmithKline
Axel Hauschild
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Caroline Robert
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Richard Kefford
Consultant or Advisory Role - GlaxoSmithKline
Vicki L. Goodman
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Julie C. Switzky
Employment or Leadership Position - GlaxoSmithKline
R. Suzanne Swann
Employment or Leadership Position - GlaxoSmithKline
Anne-Marie Martin
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Mary E. Guckert
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Michael R. W. Streit
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Dirk Schadendorf
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline